Connection

W. Garvey to Anti-Obesity Agents

Back to Details
This is a "connection" page, showing publications W. Garvey has written about Anti-Obesity Agents.
W. Garvey
Connection Strength
4.745
Anti-Obesity Agents
  1. Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program. Popul Health Manag. 2023 02; 26(1):72-82.
    View in: PubMed
    Score: 0.827
  2. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. J Manag Care Spec Pharm. 2022 Oct; 28(10):1066-1079.
    View in: PubMed
    Score: 0.797
  3. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 07; 40(7):856-862.
    View in: PubMed
    Score: 0.555
  4. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015 Jun; 4(2):287-302.
    View in: PubMed
    Score: 0.486
  5. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec; 37(12):3309-16.
    View in: PubMed
    Score: 0.463
  6. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract. 2013 Sep-Oct; 19(5):864-74.
    View in: PubMed
    Score: 0.431
  7. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
    View in: PubMed
    Score: 0.382
  8. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017 05; 25(5):857-865.
    View in: PubMed
    Score: 0.139
  9. Pharmacotherapy for Weight Management in the VHA. J Gen Intern Med. 2017 Apr; 32(Suppl 1):70-73.
    View in: PubMed
    Score: 0.138
  10. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014 Apr; 37(4):912-21.
    View in: PubMed
    Score: 0.108
  11. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep; 12(5):741-56.
    View in: PubMed
    Score: 0.106
  12. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013 Sep-Oct; 27(5):508-18.
    View in: PubMed
    Score: 0.106
  13. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb; 20(2):330-42.
    View in: PubMed
    Score: 0.095
  14. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
    View in: PubMed
    Score: 0.046
  15. Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. Obesity (Silver Spring). 2018 02; 26(2):332-339.
    View in: PubMed
    Score: 0.037
  16. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care. 2015 Aug; 38(8):1567-82.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.